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ABSTRACT
Objectives Although obesity is a risk factor for stroke, 
its impact on mortality in patients with stroke remains 
unclear. In this study, we aimed to evaluate the relationship 
between body mass index (BMI) and mortality due to 
ischaemic stroke among adults aged 20 years and above 
in Korea.
Design Retrospective cohort study.
Setting A tertiary-hospital-based stroke registry linked to 
the death records.
Participants 3599 patients admitted for ischaemic stroke 
from January 2007 to June 2013.
Outcome measures The HRs for all-cause and stroke-
related mortality were calculated using Cox proportional 
hazards models. Progression from stroke-related mortality 
was assessed using the Fine-Grey competing risk 
model, treating other-cause mortality as a competing 
risk. Adjustments were made for age, gender, smoking 
status, Charlson comorbidity index, cardiovascular or 
non-cardiovascular comorbidities, stroke severity, severity 
related to other medical conditions, complications and 
enrolment year. We repeated the analysis with stratification 
based on age groups (less than 65 vs 65 years and above).
Results For stroke-related mortality, there was no 
significant difference among the four BMI groups. The risk 
of all-cause mortality was 36% higher in the underweight 
group than in the normal weight group (long-term 
HR=1.36, 95% CI: 1.04 to 1.79), whereas the mortality 
risk of the obese group was significantly lower (HR=0.66, 
95% CI: 0.54 to 0.81). Although this relationship was not 
estimated in the younger group, it was found that obesity 
had a protective effect on the all-cause mortality in the 
elderly (long-term HR=0.66, 95% CI: 0.52 to 0.83).
Conclusions Obesity is more likely to reduce mortality 
risk than normal weight, especially in elderly patients.
InTRODuCTIOn
Obesity is one of the established risk factors 
for stroke, in which prevention guidelines 
recommend weight reduction.1 However, in 
patients who have experienced a stroke, an 
inverse relationship was reported between 
obesity and unfavourable clinical outcomes, 
such as readmission, stroke recurrence and 
mortality, in contrast to that of the general 
population.2–8 This paradox was also observed 
in other chronic diseases such as heart failure, 
diabetes, chronic kidney disease, and periph-
eral vascular disease.9–12
The obesity paradox remains to be fully 
explained and even criticised as an artificial 
finding associated with selection bias, that is, 
a confounding result due to uncontrolled risk 
factors commonly correlated with mortality 
and obesity.13–15 One obvious confounder is 
comorbidities. Some comorbidities such as 
infections or malignant diseases can cause 
unintended weight loss and death.16 Other 
significant confounders are age and stroke 
severity. In several studies on the obesity 
paradox, patients with lower body mass index 
(BMI) were older and had higher stroke 
severity, consequently causing an increased 
mortality risk.17–19 Previous studies on Korean 
patients with ischaemic stroke18 19 also showed 
that the initial relationship between obesity 
and short-term clinical outcome19 or long-
term mortality18 cease to exist after adjusting 
for stroke severity.
Comorbidities, age and stroke severity 
are the most critical outcome determi-
nants after an ischaemic stroke incident. 
Hence, in this paper, we examine the rela-
tionship between obesity-related mortality 
and all-cause mortality among patients with 
ischaemic stroke after adjusting the effect 
of stroke severity (based on the National 
Institutes of Health Stroke Scale (NIHSS) 
Strengths and limitations of this study
 ► The relationship between body mass index and 
mortality was evaluated by controlling the variables 
related to various diseases, which could not be ob-
tained in previous studies.
 ► We addressed the existence of multi-morbidity by 
Charlson comorbidity index.
 ► This is a hospital-based study involving a single ter-
tiary hospital whose data could not be generalised.
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score) and other severe comorbidities from a detailed 
registry data in a clinical setting. The NIHSS score is 
an excellent indicator of stroke severity. We also deter-
mine whether the relationship is consistent regardless 
of patients’ age.
MATeRIAlS AnD MeThODS
Data source and study subjects
The study subjects were from the Yonsei Stroke Registry, 
a hospital-based stroke registry established in 1994.20 
We identified all patients aged 20 years and above who 
were admitted for acute ischaemic stroke from January 
2007 to June 2013. The Yonsei Stroke Registry admits 
only patients with acute ischaemic stroke who were seen 
by a neurologist within 7 days of clinical onset. All of the 
patients have acute cerebral infarctions and have been 
presented to the neurologists within 7 days of onset. The 
diagnosis of cerebral infarction was based on clinical 
features related to neuroimaging studies such as CT or 
MRI, which was confirmed by the agreement of two or 
more staff neurologists. We excluded patients younger 
than 20 years and those without height or weight data. 
Registered patients were routinely followed up in the 
outpatient clinic until their death. Moreover, the deaths 
were confirmed by matching the death records and the 
cause of death obtained from the Korean National Statis-
tical Office. The causes of death were classified according 
to the International Classification of Disease, 10th revi-
sion. Furthermore, stroke-related mortality included the 
fatal stroke (I60–64),21 whereas cardiovascular-event-re-
lated mortality included I00–I99.
Variables
Obesity
Height and weight were measured at the time of registra-
tion. BMI was calculated as the ratio of weight (kg) and 
the square of height (m2). Then, the patients were clas-
sified into four groups based on their BMI at the time of 
stroke. Obese I and obese II categories were combined 
to a single obese category, and BMI levels were classified 
according to the guidelines for the Asian-Pacific popula-
tion22: underweight (BMI <18.5 kg/m2), normal weight 
(18.5≤BMI < 23 kg/m2), overweight (23≤BMI < 25 kg/m2) 
and obese (BMI ≥25 kg/m2). The normal weight group 
was used as the reference group.
Clinical outcomes
The primary outcomes were all-cause mortality in the 
short term (within 3 months), intermediate term (within 
1 year) and long term (longer than 1 year) after the 
stroke incident. Meanwhile, the secondary outcomes 
were stroke-related mortality and cardiovascular-event-re-
lated mortality, and the occurrence of those outcomes 
was ascertained based on the discharge records or death 
records.
Covariates
The initial stroke severity was evaluated using the 
NIHSS score, which ranges from 0 to 42 based on the 
15 elements of neurological examinations in various 
aspects of individual physical functions.23 To identify 
potential confounders of the relationship between BMI 
and mortality, we reviewed the literature and obtained 
the following covariates from the registry: age,24 
gender,25 26 current smoking status,1 27 28 any complication 
that occurred during admission29 and comorbidities—
including previous stroke,29 diabetes,29 30 hypercholes-
terolaemia,31 depression,32 dementia,33 anaemia,34 atrial 
fibrillation35 and active cancer. In addition to the NIHSS 
score, we included the Charlson comorbidity index (CCI) 
and cardiovascular risk parameters at admission, such 
as blood glucose level, systolic blood pressure and total 
cholesterol level at the time of the index stroke diagnosis.
Active cancer was defined as any cancer diagnosed within 
6 months before the stroke: recently recurrent cancer, 
progressive cancer, or any malignancy requiring curative 
or palliative treatment within the previous 6 months.36 
Complications included brain herniation, intracerebral 
haemorrhage, any infection (such as pneumonia, urinary 
tract infection and sepsis) and any bleeding other than 
intracerebral haemorrhage. The CCI is a widely used 
weighted composite index for comorbidities, such as 
myocardial infarction, congestive heart failure, periph-
eral vascular disease or bypass, previous cerebrovascular 
accident or transient ischaemic attack, dementia, chronic 
pulmonary disease, gastrointestinal ulcer disease, liver 
disease, moderate or severe renal disease, connective 
tissue disease or rheumatic disease, diabetes, diabetes 
with end-organ damage, AIDS, non-metastatic solid 
tumour, leukaemia, lymphoma, multiple myeloma, and 
metastatic tumour.37 Note that we did not include the age 
factor when calculating CCI.
Patients with hypertension were managed to maintain 
normal blood pressure. Shock is also a critical life-threat-
ening emergency in patients with stroke. Therefore, we 
considered both hypertension and hypotension as risk 
factors for mortality. Since blood pressure fluctuates and 
only one measurement was obtained under a stressful 
condition, we defined the lower risk range of systolic 
blood pressure as 90 to 180 mm Hg.38 It is known that 
both hypoglycaemia and hyperglycaemia can increase the 
risk of death. Since diabetes was included in the covariate 
and considering recommendations on glycaemic control 
and meta-analysis result,30 39–41 we defined the reference 
level of blood glucose as 3.9–10 mmol/L (70–180 mg/
dL). Considering that stroke treatment may last over 
7 years, all models were adjusted based on the enrol-
ment year. Using 2007 as the reference group, we created 
dummy variables representing the year of initial stroke 
hospitalisation.
Subgroup analyses were conducted based on age (less 
than 65 and 65 years and above) for all-cause mortality.
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Table 1 Summary statistics
Variables (n=3584)
Mean±SD, N (%), 
median (IQR)
Key independent variables
  BMI (kg/m2) 23.7±3.3(11.4–40.1)
  Underweight (BMI <18.5) 164 (4.6)
  Normal (18.5≤BMI < 23) 1321 (36.9)
  Overweight (23≤BMI < 25) 943 (26.3)
  Obese (BMI ≥25) 1156 (32.2)
Outcomes
  All-cause mortality
   Within 3 months 248 (6.9)
   Within 1 year 425 (11.9)
   After 1 year 824 (23.0)
  Stroke-related mortality
   Within 3 months 130 (3.6)
   Within 1 year 187 (5.2)
   After 1 year 284 (7.9)
Covariates
  NIHSS on admission 3(1–7)
  Age 66±12.4
   20–64 years 1439 (40.2)
   ≥65 years 2145 (59.8)
  Sex
   Male* 2175 (60.7)
Comorbidities
  Atrial fibrillation* 803 (22.4)
  Depression* 197 (5.5)
  Dementia* 107 (3.0)
  Previous stroke or transient 
ischaemic attack*
470 (13.1)
  Anaemia* 616 (17.2)
  Active cancer* 205 (5.7)
  Liver disease* 109 (3.0)
  Moderate or severe renal disease* 300 (8.4)
  Diabetes* 1138 (31.8)
  Hypercholesterolaemia* 747 (20.8)
  Charlson comorbidity index 1 [0–2)
  Current smoking* 854 (23.8)
Initial systolic blood pressure (mm 
Hg)
  90≤SBP < 180 2913 (81.3)
  Shock (SBP <90)* 12 (0.3)
  Extremely high blood pressure 
(SBP ≥180)*
659 (18.4)
Initial blood glucose (mmol/L)
  3.9≤glucose < 10 2935 (81.9)
  Hypoglycaemia (glucose <3.9)* 15 (0.42)
Continued
Statistical analysis
The characteristics of the study groups were analysed 
using analysis of variance tests, and Kruskal-Wallis test 
and χ2 tests were used for continuous variables and cate-
gorical variables, respectively. Kaplan-Meier analysis was 
used to determine the relationship between categorical 
BMI and all-cause or stroke-related mortality. We used 
multivariate Cox proportional hazard models to analyse 
the relationship between BMI and mortality within 
3 months, 1 year and over 1 year. The multivariate models 
were adjusted for age, gender and smoking status. The 
same analysis was conducted by additionally adjusting 
for comorbidities, CCI, shock or extremely high blood 
pressure, hypoglycaemia or hyperglycaemia at admission, 
total cholesterol level at admission, NIHSS score, any 
complications, enrolment year, treatment modalities (any 
thrombolysis, tissue plasminogen activator use, intra-ar-
terial thrombolysis, mechanical thrombectomy and stent 
insertion), and statin use. Progression from stroke-related 
mortality was assessed using the Fine-Grey competing risk 
model, treating other-cause mortality as a competing risk. 
We also performed competing risk analysis with cardio-
vascular-event-related death as the primary event of 
interest and non-cardiovascular mortality as a competing 
event. Stratified analyses based on the patient’s age group 
were performed. However, because dementia and hypo-
glycaemia were rare in younger patients, we excluded 
these variables for ages less than 65 years in the subgroup 
analysis. Furthermore, statistical analyses were performed 
using Stata V.14 (College Town, TX, USA).
Patient and public involvement
Patients and the public were not involved in this analysis.
ReSulTS
Sample characteristics
A total of 3599 patients with ischaemic stroke aged 20 
years and older were identified from the registry from 
January 2007 to June 2013. In all, 15 patients (0.4%) were 
excluded because of missing height or weight data, and 
thus, only 3584 patients remained as the final sample. 
Compared with patients with accurate height and weight 
information, those without such data were older, had a 
severe stroke and showed higher short-term mortality.
Table 1 summarises the baseline characteristics of 
the final sample. The mean age of the studied patients 
was 66 (range, 20–104) years. The mean BMI was 
23.7 kg/m2; 164 (4.6%) patients were underweight, 
1321 (36.9%) were normal weight, 943 (26.3%) were 
overweight and 1156 (32.2%) were obese. Patients were 
followed up for a mean period of 1133 days after the 
index event. A total of 824 patients (23%) died, and 
the mean duration until death was 545 days, where 284 
patients (7.9%) died of a stroke, with a mean duration 
until stroke-related death of 360 days. In the subgroup 
of patients aged less than 65 years, 159 (11.1%) died 
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Variables (n=3584)
Mean±SD, N (%), 
median (IQR)
  Poorly controlled hyperglycaemia 
(glucose ≥10)*
634 (17.7)
  Initial total cholesterol (mg/dL) 181±43
Subtypes of ischaemic stroke
  Large artery atherosclerosis 741 (20.7)
  Cardioembolism 980 (27.3)
  Small vessel occlusion 319 (8.9)
  Stroke of other determined 
aetiology
86 (2.4)
  Stroke of undetermined aetiology 
because of incomplete evaluation
10 (0.3)
  Stroke of undetermined aetiology 
because of negative evaluation
781 (21.8)
  Stroke of undetermined aetiology 
because of two or more causes
667 (18.6)
  Any complications* 588 (16.4)
Treatment*
  Any thrombolysis 407 (11.4)
  Tissue plasminogen activator 275 (7.7)
  Intra-arterial thrombolysis 163 (4.6)
  Mechanical thrombectomy 126 (3.5)
  Stent insertion 111 (3.1)
  Antiplatelet 1146 (32.0)
  Anticoagulation 206 (5.8)
  Statin 610 (17)
Fiscal year of stroke onset
  2007 522 (14.6)
  2008 541 (15.1)
  2009 642 (17.9)
  2010 512 (14.3)
  2011 561 (15.6)
  2012 523 (14.6)
  2013 283 (7.9)
*Dummy variables.
BMI, body mass index; NIHSS, National Institute of Health Stroke 
Scale; SBP, systolic blood pressure.
Table 1 Continued
during the follow-up period, whereas the mortality of 
elderly patients aged 65 years and above was 31% (665 
patients).
Table 2 shows the baseline characteristics among 
obesity subgroups. Underweight patients were older and 
more likely to have higher NIHSS scores, atrial fibrilla-
tion, anaemia, active cancer, shock and complications. 
Obese patients were younger and more likely to have 
diabetes, hypercholesterolaemia and higher initial total 
cholesterol.
Stroke-related mortality and cardiovascular-event-related 
mortality in the total population
Stroke-related mortality was highest in the underweight 
patients and lowest in the obese patients (see figure 1A). 
After adjustment of age, gender and smoking status, 
the overweight had a lower probability of long-term 
mortality—subdistribution HR (SHR)=0.73, 95% CI: 0.54 
to 0.99—(see table 3, Model 1). However, after further 
adjustment of comorbidities, the obesity paradox disap-
peared (see table 3, Model 2). For cardiovascular-event-re-
lated mortality, the overweight and obese groups had 
a lower probability of long-term mortality (SHR=0.72, 
95% CI: 0.55 to 0.95 for the overweight group; SHR=0.67, 
95% CI: 0.51 to 0.89 for the obese group) in Model 1. 
After further adjustment, the obese group still had a lower 
probability of long-term mortality (SHR=0.66, 95% CI: 
0.49 to 0.90; see table 3, Model 2).
All-cause mortality in the total population
In the unadjusted analysis, all-cause mortality increased 
with lower BMI (see figure 1B). The all-cause mortality 
risks in covariate-adjusted analysis remained higher in 
the underweight group than in the normal weight group 
for all investigated durations (HR=1.55, 95% CI: 1.00 to 
2.42 for 3-month mortality; HR=1.54, 95% CI: 1.09 to 
2.18 for 1-year mortality; HR=1.43, 95% CI: 1.09 to 1.87 
for long-term mortality). By contrast, after adjusting for 
the confounding variables, the obese group had a lower 
risk than the normal weight group by 19% for 3-month 
mortality (HR=0.81, 95% CI: 0.56 to 1.16), 27% for 1-year 
mortality (HR=0.73, 95% CI: 0.55 to 0.99) and 34% for 
mortality of 1 year and above (HR=0.66, 95% CI: 0.54 to 
0.82; see table 4).
All-cause mortality stratified by age group
The all-cause mortality was lower in the higher BMI groups 
in both elderly (of age 65 years and above) and younger 
(of age less than 65 years) subgroups (see figure 2A and 
B) in the unadjusted analyses. The obesity paradox was 
still observed even after adjustment for age, gender and 
smoking status and was more evident in the younger 
group in all investigated durations (see table 4, Model 
1). However, after further adjustment for comorbidities, 
such associations disappeared in the younger group. By 
contrast, in the older age group, the mortality risk was 
maintained: higher mortality risk in the underweight 
group (HR=1.50, 95% CI: 1.03 to 2.19 for 1-year mortality; 
HR=1.42, 95% CI: 1.06 to 1.92 for long-term mortality) 
and lower mortality risk in the obese group (long-term 
HR=0.65, 95% CI: 0.52 to 0.83; see table 4, Model 2).
DISCuSSIOn
This study showed that the obesity paradox is not evident 
in stroke-related mortality. By contrast, the obesity 
paradox was highly associated with the all-cause death 
even after accounting for potential confounding of pre-ex-
isting comorbidities. We also found that such association 
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Table 2 Univariate analysis of covariates between obesity groups
Covariates
Underweight
(n=164)
Normal weight
(n=1321)
Overweight
(n=943)
Obese
(n=1156) P value
NIHSS on admission 5 (2–14) 4 (2–8) 3 (1–7) 3 (1–6) <0.001
Age 71.7±14.3 67.6±12.4 66.0±11.6 63.3±12.2 <0.001
Sex, male 80 (48.8) 773 (58.5) 640 (67.9) 682 (59) <0.001
Atrial fibrillation 55 (33.5) 316 (23.9) 211 (22.4) 221 (19.1) <0.001
Depression 17 (10.4) 83 (6.3) 47 (5.0) 50 (4.3) 0.006
Dementia 8 (4.9) 42 (3.2) 34 (3.6) 23 (2.0) 0.06
Previous stroke or transient 
ischaemic attack
27 (16.5) 161 (12.2) 119 (12.6) 163 (14.1) 0.284
Anaemia 63 (38.4) 283 (21.4) 128 (13.6) 142 (12.3) <0.001
Active cancer 13 (7.9) 91 (6.9) 52 (5.5) 49 (4.2) 0.022
Liver disease 5 (3.1) 30 (2.3) 29 (3.1) 45 (3.9) 0.138
Moderate or severe renal disease 21 (12.8) 130 (9.8) 66 (7.0) 83 (7.2) 0.006
Diabetes 37 (22.6) 389 (29.5) 290 (30.8) 422 (36.5) <0.001
Hypercholesterolaemia 23 (14.0) 245 (18.6) 189 (20.0) 290 (25.1) <0.001
Charlson comorbidity index 1 [0–2.5) 1 [0–2) 1 [0–2) 1 [0–2) 0.016
Current smoking 27 (16.5) 309 (23.4) 244 (25.9) 274 (23.7) 0.065
Shock (SBP <90) 3 (1.8) 6 (0.5) 2 (0.2) 1 (0.1) 0.003
Extremely high blood pressure (SBP 
≥180)
33 (20.1) 234 (17.8) 168 (17.8) 224 (19.4) 0.640
Initial hypoglycaemia (glucose <3.9) 0 (0) 7 (0.5) 5 (0.5) 3 (0.3) 0.559
Poorly controlled hyperglycaemia 
(glucose ≥10)
23 (14.0) 219 (16.6) 165 (17.5) 227 (19.6) 0.129
Initial total cholesterol (mmol/L) 171±40 179±42 180±42 186±45 <0.001
Large artery atherosclerosis 28 (17.1) 255 (19.3) 180 (19.1) 278 (24.1) 0.006
Cardioembolism 58 (35.4) 372 (28.2) 264 (28.0) 286 (24.7) 0.019
Small vessel occlusion 14 (8.5) 112 (8.5) 90 (9.5) 103 (8.9) 0.850
Stroke of other determined aetiology 4 (2.4) 32 (2.4) 21 (2.2) 29 (2.5) 0.980
Stroke of undetermined aetiology 
because of incomplete evaluation
1 (0.6) 2 (0.2) 3 (0.3) 4 (0.4) 0.647
Stroke of undetermined aetiology 
because of negative evaluation
29 (17.7) 279 (21.1) 212 (22.5) 261 (22.6) 0.448
Stroke of undetermined aetiology 
because of two or more causes
30 (18.3) 269 (20.4) 173 (18.4) 195 (16.9) 0.168
Any complications 50 (30.5) 239 (18.1) 133 (14.1) 166 (14.4) <0.001
Any thrombolysis 26 (15.9) 158 (12.0) 106 (11.2) 117 (10.1) 0.136
Tissue plasminogen activator 19 (11.6) 107 (8.1) 62 (6.6) 87 (7.5) 0.137
Intra-arterial thrombolysis 12 (7.3) 71 (5.4) 43 (4.6) 37 (3.2) 0.020
Mechanical thrombectomy 4 (2.4) 49 (3.7) 41 (4.4) 32 (2.8) 0.209
Stent insertion 5 (3.1) 40 (3.0) 42 (4.5) 24 (2.1) 0.020
Antiplatelet 58 (35.4) 410 (31.0) 315 (33.4) 363 (31.4) 0.482
Anticoagulation 9 (5.5) 79 (6.0) 54 (5.7) 64 (5.5) 0.969
Statin 31 (18.9) 192 (14.5) 186 (19.7) 201 (17.4) 0.011
NIHSS, National Institute of Health Stroke Scale; SBP, systolic blood pressure.
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Figure 1 Survival curves for (A) stroke-related mortality 
and (B) all-cause mortality in patients with ischaemic stroke 
according to their body mass index.
Table 3 Adjusted HRs of the obesity status on stroke-related mortalities and cardiovascular-event-related mortality
Variables
3 months 1 year After 1 year
SHR 95% CI SHR 95% CI SHR 95% CI
Stroke-related mortality
  Model 1*
   Underweight 1.63 0.91 to 2.91 1.52 0.93 to 2.48 1.39 0.91 to 2.12
   Normal weight 1.00 1.00 1.00
   Overweight 0.68 0.42 to 1.11 0.70 0.47 to 1.03 0.73 0.54 to 0.99
   Obese 1.01 0.65 to 1.57 0.81 0.56 to 1.18 0.76 0.56 to 1.03
  Model 2†
   Underweight 1.12 0.61 to 2.05 1.56 0.93 to 2.61 1.42 0.91 to 2.23
   Normal weight 1.00 1.00 1.00
   Overweight 0.85 0.55 to 1.34 0.84 0.55 to 1.26 0.83 0.61 to 1.15
   Obese 0.87 0.56 to 1.34 0.92 0.61 to 1.38 0.82 0.58 to 1.14
Cardiovascular-event-related 
mortality
  Model 1*
   Underweight 1.23 0.70 to 2.16 1.15 0.71 to 1.86 1.08 0.72 to 1.62
   Normal weight 1.00 1.00 1.00
   Overweight 0.69 0.45 to 1.05 0.71 0.51 to 0.99 0.72 0.55 to 0.95
   Obese 0.83 0.55 to 1.25 0.70 0.49 to 0.99 0.67 0.51 to 0.89
  Model 2†
   Underweight 1.12 0.62 to 2.05 1.05 0.63 to 1.77 0.98 0.63 to 1.53
   Normal weight 1.00 1.00 1.00
   Overweight 0.85 0.54 to 1.33 0.86 0.60 to 1.23 0.83 0.63 to 1.11
   Obese 0.87 0.56 to 1.35 0.73 0.50 to 1.07 0.66 0.49 to 0.90
*Model 1 was adjusted for age, gender and smoking status.
†Model 2 adjusted the following covariates in addition to what were controlled in Model 1: comorbidities (diabetes, old stroke, atrial 
fibrillation, active cancer, anaemia, renal disease, liver disease, hypercholesterolaemia, depression, dementia, any complications, initial 
systolic blood pressure status, total cholesterol, initial glucose level and Charlson comorbidity index), enrolment year, stroke severity 
measured using the NIHSS score, treatment modalities (any thrombolysis, tissue plasminogen activator, intra-arterial thrombolysis, 
mechanical thrombectomy and stent insertion) and statin use.
NIHSS, National Institute of Health Stroke Scale; SHR, subdistribution hazard ratio.
exists only in the elderly patients, whereas it vanishes after 
covariate adjustment in the younger age group.
A study by Dehlendorff et al15 reported no obesity 
paradox for stroke-related short-term mortality, which 
agrees with the findings of this study. Notably, the study 
mentioned above only considered death incidence within 
the first month of post-stroke,15 whereas we considered 
later deaths caused by recurrent stroke incidences. 
The effects of obesity on all-cause mortality in patients 
with ischaemic stroke revealed that higher BMI slightly 
increases the survival rate across several conditions, given 
that all-cause mortality denotes the overall survival across 
all causes of death. Notably, our results are consistent with 
previous findings on the obesity paradox in patients with 
stroke. For instance, a study on stroke survivors in Korea 
revealed a relatively low 1-year all-cause mortality without 
any evident paradox for 30-day and 90-day all-cause mortal-
ities.17 Findings from this present study also indicate that 
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Table 4 All-cause mortality stratified by age group
Variables
3 months 1 year After 1 year
HR 95% CI HR 95% CI HR 95% CI
Model 1*
  Total cohort
   Underweight 1.96 1.31 to 2.93 1.89 1.37 to 2.59 1.61 1.25 to 2.09
   Normal weight 1.00
   Overweight 0.60 0.42 to 0.85 0.70 0.54 to 0.90 0.83 0.70 to 0.98
   Obese 0.67 0.48 to 0.94 0.63 0.48 to 0.82 0.63 0.53 to 0.82
  Age <65 years
   Underweight 3.75 1.66 to 8.47 3.49 1.36 to 7.22 2.54 1.32 to 4.89
   Normal weight 1.00 1.00 1.00
   Overweight 0.81 0.41 to 1.56 0.83 0.48 to 1.46 0.91 0.61 to 1.34
   Obese 0.28 0.12 to 0.63 0.53 0.30 to 0.91 0.58 0.39 to 0.86
  Age≥65 years
   Underweight 1.57 1.00 to 2.47 1.59 1.12 to 2.25 1.46 1.10 to 1.93
   Normal weight 1.00 1.00 1.00
   Overweight 0.54 0.36 to 0.81 0.67 0.51 to 0.89 0.82 0.68 to 0.99
   Obese 0.89 0.62 to 1.27 0.70 0.52 to 0.93 0.6 0.54 to 0.82
Model 2†
  Total cohort
   Underweight 1.55 1.00-2.47 1.54 1.09-2.18 1.43 1.09-1.87
   Normal weight 1.00 1.00 1.00
   Overweight 0.78 0.54-1.13 0.89 0.69-1.14 0.98 0.82-1.16
   Obese 0.81 0.56-1.16 0.73 0.55-0.99 0.66 0.54-0.82
  Age <65 years
   Underweight 0.64 0.15 to 2.82 0.73 0.22 to 2.44 0.98 0.41 to 2.35
   Normal weight 1.00 1.00 1.00
   Overweight 1.27 0.59 to 2.74 1.36 0.73 to 2.54 1.43 0.92 to 2.21
   Obese 0.43 0.17 to 1.12 0.72 0.40 to 1.31 0.77 0.49 to 1.21
  Age≥65 years
   Underweight 1.49 0.92 to 2.41 1.50 1.03 to 2.19 1.42 1.06 to 1.92
   Normal weight 1.00 1.00 1.00
   Overweight 0.59 0.39 to 0.91 0.77 0.58 to 1.02 0.91 0.75 to 1.10
   Obese 0.96 0.65 to 1.44 0.73 0.52 to 1.03 0.65 0.52 to 0.83
*Model 1 was adjusted for age, gender and smoking status.
†Model 2 adjusted the following covariates in addition to what were controlled in Model 1: comorbidities (diabetes, old stroke, atrial 
fibrillation, active cancer, anaemia, renal disease, liver disease, hypercholesterolaemia, depression, dementia, any complications, initial 
systolic blood pressure status, total cholesterol, initial glucose level and Charlson comorbidity index), enrolment year, stroke severity 
measured using the NIHSS score, treatment modalities (any thrombolysis, tissue plasminogen activator, intra-arterial thrombolysis, 
mechanical thrombectomy and stent insertion) and statin use.
NIHSS, National Institute of Health Stroke Scale.
the underweight group persistently had a higher all-cause 
mortality risk during short-term, intermediate-term and 
long-term follow-up periods, and the mortality risk of 
the overweight group is similar to that of the normal 
weight group at all points. Furthermore, our study was 
corroborated by previous findings on increased mortality 
risk among underweight stroke survivors. Underweight 
is consistently associated with increased mortality after 
stroke,3 5 6 15 17 18 42 43 although the impact of obesity on 
mortality was reported in a conflicting direction.
After controlling the confounding factors, we observed 
that the obesity paradox for the all-cause mortality is only 
found in patients aged 65 years and above. It has been 
shown that adults aged 65 years and above experience 
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Figure 2 Survival curves in (A) elderly and (B) younger 
patients with ischaemic stroke according to their body mass 
index.
weight loss more frequently than weight gain.44 In addi-
tion, weight loss has been shown to be associated with 
higher mortality risk in older adults44 45 and even predict 
mortality independent from chronic disease.46 47 Another 
possible explanation for such obesity paradox is a subset 
of obese people classified as metabolically healthy obese.48 
These people seem to be more resistant to the develop-
ment of obesity-related metabolic diseases. In a study with 
elderly Koreans aged 60 years and above, the metaboli-
cally non-healthy normal weight people were observed 
to have a remarkably higher risk of all-cause and cardio-
vascular disease mortality than the overweight or obese 
people without metabolic syndrome.48
As far as we know, only a few studies have compared 
the obesity paradox based on age group4 17 43; even so, the 
findings were inconsistent. The findings of some of those 
studies agreed with the results obtained in this study and 
reported the obesity paradox in patients aged 65 years 
and above.4 42 Towfighi et al4 reported that obesity is asso-
ciated with reduced mortality only among elderly survi-
vors.4 A study with women aged 50–79 years also showed 
that being overweight or obese is associated with low post-
stroke mortality.42 Meanwhile, in contrast with our results, 
some studies reported that the obesity paradox is more 
prominent in younger patients17 43 and more prominent 
in patients with stroke aged less than 65 years. However, 
it is worth noting that in our study, the obesity paradox in 
the younger age group became statistically insignificant 
after adjustment of detailed comorbidities, despite being 
significant and even more noticeable in the younger 
age group before the adjustment. This shows that the 
conflicting results on the obesity paradox in the younger 
age group might be due to the different methods used in 
controlling the critical confounding variables in different 
studies. Considering the relatively small number of partic-
ipants and deaths in the younger subgroup, larger-scale 
studies with better control of confounders are needed 
to enhance further the understanding of the obesity 
paradox based on age groups. Nevertheless, our findings 
in this study suggest that, at least in elderly patients with 
stroke, obesity is not necessarily a risk for mortality.
The obesity paradox in chronic diseases could be 
explained through biological mechanisms focusing on 
the advantage of excess fat during illness.49 For instance, 
weight loss after stroke is a commonly observed phenom-
enon, which is explained by various mechanisms such as 
sympathetic activation, fever and inflammation.50 Indi-
viduals may lose homeostatic capacity and become more 
susceptible to the catabolic effect of chronic morbidity 
or complications. Owing to better metabolic reserves in 
obese patients, unfavourable metabolic dysregulation 
might be less common in obese patients.50
Despite the biological explanation, some studies 
also raised concerns about inadequate control of 
confounding variables and reverse causation of the 
underlying reasons for the observed obesity paradox. 
Reverse causation occurs when low BMI is not an inde-
pendent risk factor; instead, it is a consequence of 
underlying conditions that cause weight loss and then 
lead to death. However, several studies reported that the 
mortality risk does not change after excluding patients 
with life-threatening diseases such as cancer or those who 
died early in the follow-up period.51 52 Several studies, 
including this present study, showed that confounders 
such as smoking and comorbidities could not entirely 
explain the obesity paradox.2 3 5 6 17 42 A related empir-
ical concern regarding the obesity paradox is a collid-
er-stratification bias that results from conditioning 
the common effects of exposure and outcome.49 For 
example, atrial fibrillation, a common risk factor for 
both ischaemic stroke and mortality,1 is a higher risk for 
mortality than obesity among patients with stroke; thus, 
one could falsely observe the protective effect of obesity 
on mortality when not adjusting for atrial fibrillation 
in obesity regression on stroke-related mortality. This 
highlights the importance of comprehensive control 
of comorbidities and stroke severity in estimating the 
obesity paradox in patients with stroke as in the current 
study. We acknowledge that there are conflicting find-
ings in previous studies regarding the collider bias and 
obesity paradox after controlling for it.15 53 This study 
adjusted for stroke severity and various comorbidi-
ties using CCI to estimate the net effect of obesity on 
mortality in patients with stroke considering the effect 
that may result because of the uncertainty of the kind of 
relationship that exists between various comorbidities 
with obesity and mortality.
Notwithstanding, this study has several limitations. 
First, this is a hospital-based study involving a single 
tertiary hospital whose data could not be generalised. 
However, this could also be an advantage of the study. 
Since patients received relatively uniform treatments 
at the same hospital, a potential confounder from 
different treatments could be minimised. Moreover, we 
retrieved the data from a registry in which the clinical 
information had been maintained in a standard pre-de-
fined way. Second, we evaluated the body composition 
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as BMI, which cannot differentiate between elevated 
body fat content and preserved or increased lean mass.54 
Measurement of fat distribution such as waist-to-hip 
ratio or waist circumference could probably be more 
suitable in assessing the effect of obesity on stroke-re-
lated mortality. Third, in the analysis, we excluded 
patients without BMI information. The missing weight 
or height data could be due to the patient’s extremely 
severe status or inability to stand up. These patients 
without recorded body weight and height informa-
tion apparently had a higher NIHSS score and higher 
mortality rate in the unadjusted analysis. Therefore, 
in this study, it is possible that the obesity paradox was 
underestimated by excluding the patients with missing 
BMI data.
Despite the shortcomings, this study made several 
significant contributions. First, we evaluated the rela-
tionship between BMI and mortality risk by controlling 
the variables related to various diseases, which could 
not be obtained in previous studies, including some 
potential confounders such as active cancer, depression, 
dementia, anaemia, other medical severity at admission 
and complications during stroke treatment. Second, 
as mentioned earlier, we addressed the existence of 
multi-morbidity by CCI. To the best of our knowledge, 
CCI has not been considered a confounding variable in 
any study in analysing the effect of the obesity paradox 
on mortality in stroke survivors.2–6 15 17 18 42 43 55 Third, the 
covariates measurements were rigorously performed. 
Previous studies included initial blood pressure or 
glucose level as a surrogate marker of cardiovascular 
disease severity. However, they did not mention the 
risk associated with the assessment method but only 
considered the increment in those levels as a severity 
indicator.2 17 55
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